Search results
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
- Careers
At Intellia, we are revolutionizing medicine by harnessing...
- Pipeline
Intellia Therapeutics, Inc. Intellia Therapeutics and the...
- Investors & Media
Intellia Therapeutics to Present the First-Ever Clinical...
- Press Releases
CAMBRIDGE, Mass. , June 14, 2024 (GLOBE NEWSWIRE) --...
- About
Learn more about Intellia, a clinical-stage genome editing...
- Our Science
Intellia is engineering T cells against specific cancer...
- Careers
Intellia is a biotechnology company that develops CRISPR-based genome editing treatments for genetic, oncological and immunological diseases. Learn about its mission, values, leadership, partners and technologies.
1 day ago · Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies.
1 day ago · About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body.
Intellia Therapeutics is a gene editing company developing NTLA-2001, a single-dose CRISPR therapy for transthyretin (ATTR) amyloidosis. The company announced the first patient dosed in the Phase 3 MAGNITUDE trial of NTLA-2001 in March 2024.
Oct 18, 2023 · NTLA-2001 is the first in vivo CRISPR-based gene editing therapy to enter late-stage clinical development. It is a potential single-dose treatment for transthyretin (ATTR) amyloidosis, a rare and fatal disease caused by gene mutations.
Intellia is a biotechnology company that develops CRISPR-based therapies for genetic diseases. Learn about CRISPR, its types of edits, and Intellia's in vivo and ex vivo approaches.
